Clinical Trial Search

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants

Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589

Primary: Response Rate, Defined as the Number of Patients Achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) — 5; 2; 3; 1 Participants

Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 0; 0; 0; 0 Participants

Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…

Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants

Primary: Event-free Survival — 29 percentage of participants

Primary: The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) — 0 participants

Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants

Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…

Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Participants Achieving a Complete Response — 51 Participants

Primary: Number of Participants With Adverse Events — 8 Participants

Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants

Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change

Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients

Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. — 0 participant response

Primary: The Primary Objective of the Study is to Test Whether the NFKB2 Rearrangement Can Guide the Selection of Treatment (Ixazomib Plus Dexamethasone (Id) or Ixazomib Plus…

Primary: Overall Response Percentage — 0.077 percentage of responders

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants

Primary: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)…

Primary: Confirmed Overall Response Rate (Stringent Complete Response [sCR], Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) With Single…

Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants

Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…

Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients

Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597

Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…

Primary: Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory…